It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

14833

Effects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteers



Original Research

(4543) Total Article Views


Authors: André C Schmidt, Burkhard Flick, Elke Jahn, Peter Bramlage

Published Date September 2008 Volume 2008:4(4) Pages 905 - 915
DOI: http://dx.doi.org/10.2147/VHRM.S3020

André C Schmidt1, Burkhard Flick1, Elke Jahn2, Peter Bramlage3

1Charité – Universitätsmedizin Berlin, Institute for Clinical Pharmacology and Toxikology, Berlin, Germany; 2Berlin-Chemie AG, Clinical Research and Medical Information, Berlin, Germany; 3Institute for Clinical Pharmacology, Medical Faculty Carl Gustav Carus, TU Dresden, Germany

Objective: To assess the effect of nebivolol, a highly selective third generation β1-adrenoceptor antagonist with an endothelium-dependent vasodilatory action, on smoking-induced endothelial dysfunction.

Research design and methods: This open-label study examined the effect of 14 daily doses of 5 mg nebivolol on forearm blood flow in 21 healthy, young, male, light smokers (≤5 cigarettes/day), measured by plethysmography on Days 1, 7, and 14. The primary endpoint was the difference in forearm blood flow after smoking one standard cigarette from baseline (Day 1) until treatment end on Day 14. Secondary outcomes included the difference in forearm blood flow between Day 1 and Day 7 compared with Day 14 before and after smoking, the effect of nebivolol on blood coagulation parameters, high-sensitive-C-reactive protein (hs-CRP), and the safety and tolerability of nebivolol.

Results: Nebivolol for 14 days did not significantly affect forearm blood flow after smoking. On Day 7 of nebivolol treatment, forearm blood flow after smoking was significantly greater than blood flow before smoking (increase of 0.44 mL/min; p = 0.00656). Serum level of hs-CRP showed a marked decrease from Day 1 to Day 14. No changes in coagulation parameters were observed over the course of nebivolol treatment. Nebivolol was well tolerated throughout the study.

Conclusions: The increase in forearm blood flow and the marked decrease in hs-CRP over 14 days of treatment suggest that nebivolol has a positive effect on endothelial function in light smokers, but larger studies are required to confirm these observations.

Keywords: C-reactive protein, endothelial dysfunction, nebivolol, nitric oxide (NO), smoking




Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read:

  • ACC 2014

    We will attend the 2014 American College of Cardiology Scientific Session and Expo (ACC) on March 29-31, 2014. Stop by booth 3217 to talk with us.

  • Like us on Facebook

    Click the blue link above to become a part of our Facebook community.